Lv3
310 积分 2023-12-30 加入
Trastuzumab deruxtecan in hormone receptor–positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
1天前
已完结
Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF
13天前
已完结
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
13天前
已关闭
Cancer Therapy and Oral Mucositis
13天前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
22天前
已完结
Insights from ESMO Immuno-Oncology Congress 2025
27天前
已完结
[Expert consensus on the out-of-hospital management of myelosuppression associated with oncological treatment (2025 edition)]
30天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
1个月前
已完结
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study
1个月前
已完结
[Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related skin adverse reactions (2024 edition)]
2个月前
已完结
皖公网安备34019202002308
